


**Supplemental information**

**LINC00941 promotes glycolysis in pancreatic  
cancer by modulating the Hippo pathway**


**Ming Xu, Ran Cui, Lunhe Ye, Yongkun Wang, Xujing Wang, Qiqi Zhang, Kaijing  
Wang, Chunxiu Dong, Wenjun Le, and Bo Chen**

### Supplementary figure 1




Statistical results of LINC00941 expression detected by in situ hybridization

### Supplementary figure 2




The efficiency of LINC00941 overexpression in PDAC cells

### Supplementary figure 3




Transcriptional activity assay of TEAD1 in LINC00941 silenced PANC1 cell.

### Supplementary figure 4



Mutant YAP1 ectopic expression in PDAC cells detected by WB


### Supplementary figure 5



LINC00941 facilitates the interaction of MST1 and PP2A

A. ECAR analysis of control, WT or ( $\Delta$ 800-1500) LINC00941 overexpression PANC1 cell. B. Cell viability assay of control, WT or ( $\Delta$ 800-1500) LINC00941 overexpression PANC1 cell. C. Statistical results of relative PP2A intensity in MST1 IP experiment. D. Co-IP assays were performed with PP2A antibody in LINC00941 control and knockdown cells, following PP2A and MST1 detection.

## Supplementary figure 6



PP2A mediated the LINC009401 induced hippo pathway activation and cancer cell growth.

A. TEAD1transcriptional activity assay of LINC00941 overexpressed BXPC-3 and CFPAC-1 cells upon PP2A knockdown or not. B-C. ECAR analysis (B) and cell viability assay(C) of control and LINC00941 overexpressed SW1990 upon PP2A knockdown or not.

**Supplementary table 1**

Q-PCR primers used in this study

Target name	Forward sequence	Reverse sequence
GLUT1	GGCCAAGAGTGTGCTAAAGAA	ACAGCGTTGATGCCAGACAG
HK2	GAGCCACCACTCACCCACT	CCAGGCATTGGCAATGTG
GPI	CAAGGACCGCTTCAACCACTT	CCAGGATGGGTGTGTTGACC
PFKFB3	TTGGCGTCCCCACAAAAAGT	AGTTGTAGGAGCTGTACTGCTT
GAPDH	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCATACTTCTCATGG
ALDOA	ATGCCCTACCAATATCCAGCA	GCTCCCAGTGGACTCATCTG
PGAM1	GTGCAGAACAGAGAGCGATCCG	CGGTTAGACCCCCATAGTGC
ENO1	AAAGCTGGTGCCGTTGAGAA	GGTTGTGGTAAACCTCTGCTC
PKM2	ATGTCGAAGCCCCATAGTGAA	TGGGTGGTGAATCAATGTCCA
LDHA	ATGGCAACTCTAAAGGATCAGC	CCAACCCCAACAACGTAAATCT

**Supplementary table 2**

CHIP-PCR primers used in this study

Target name	Forward sequence	Reverse sequence
GLUT1	TTGAGACTCAGAGAGGTGTGC	GGCTACTGACCACAGTCTG
HK2	GAGCCACCACTCACCCACT	CCAGGCATTGGCAATGTG
LDHA	GCTCCTCCTGAGGCTATCTA	ACCTCTGGCCTGTATTCT T